Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes
Authors' conclusion
Initiation of Omnipod 5 was associated with durable glycaemic improvements. Preliminary data generate the hypothesis that retinopathy progression may be concentrated among individuals with baseline HbA1c above target range.
Study context
- Population
- Adults with T1D using Omnipod 5 hybrid closed-loop system; 63% female, median age 28 years, median BMI 27.0 kg/m², median diabetes duration 16.0 years; 52% transitioned from MDI
- Participants
- 100 adults
- Exposure
- Before vs after Omnipod 5 initiation
- Outcome
- HbA1c
- Follow-up
- 12 months
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
TIR · 12 months · n = 86
P < 0.001
Glycaemic improvement by baseline time in range (TIR)
- Significant glycaemic improvements observed by 3 months
- Greatest glycaemic improvements in those with lower TIR at baseline
Safety
- Retinopathy progression, all with baseline HbA1c > 53 mmol/mol
- 10 individuals
Original publication
Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes. Diabetes Obes Metab. Published 20 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →